TITLE:
A Retrospective Chart Assessment of Clinical Outcomes after Amniotic Suspension Allograft Is Used during Spinal Arthrodesis Procedures
AUTHORS:
Joseph A. Sclafani, Kevin Liang, Darcy Mosley, Mark Prevost
KEYWORDS:
Lumbar Fusion, Spine Surgery, Stem Cells, Clinical Outcome
JOURNAL NAME:
Surgical Science,
Vol.7 No.3,
March
23,
2016
ABSTRACT: Study Design: This retrospective, non-randomized study was designed to
evaluate one-year clinical outcomes in a cohort of patients treated with an
amniotic suspension allograft as an adjunct to lumbar interbody fusion.
Methods: A single-center chart review was conducted to collect pre-operative
and peri-operative data for patients at or beyond the one year post-operative
time point. Results: Patients underwent either anterior (n = 22) or posterior
(n = 65) lumbar interbody fusion. There were six reoperations reported:
pseudarthrosis repair (n = 1), adjacent level decompression (n = 2), removal of
symptomatic instrumentation (n = 3). Overall VAS score improved from 7.8 ± 1.7
to 5.5 ± 2.4 at 1 year post-op (n = 86, p = 0.0001) and overall ODI score improved from 55 ± 16 to 42 ± 19 at 1 year
post-op (n = 85, p = 0.0001).
Patients that were 59 years old or older at the time of surgery reported
greater improvement in VAS score (3.6 ± 2.3 point improvement, n = 31) than
patients younger than 59 at the time of surgery (1.7 ± 2.2 point improvement, n
= 55, p = 0.0005). There was not a
significant difference in outcome measures between groups when the data were
stratified based on patient BMI, tobacco use, previous surgery, or a primary
indication of pseudarthrosis repair. Conclusions: These results indicate that
there is a significant clinical improvement when amniotic suspension allograft
is used during interbody fusion. Patient groups with increased risk of
non-union (increased age, previous pseudarthrosis, and tobacco users)
demonstrated improvement in one year post-op outcome measures. Improved
clinical outcome implies a high rate of successful arthrodesis in both high and
low risk patient populations.